Pasteurella multocida toxoid vaccines
This invention provides vaccine compositions, methods of producing same and methods for protecting porcine animals against disease associated with infection by toxigenic Pasteurella multocida. The vaccines of this invention contain effective amounts of a P. multocida bacterin with a cell-bound toxoid and, optionally, a P. multocida free toxoid.
Latest Pfizer Inc. Patents:
Claims
1. A vaccine composition comprising an immunogenic amount of a Pasteurella multocida bacterin, said bacterin comprising a cell-bound toxoid, an immunogenic amount of an alkaline-toxoided Pasteurella multocida cell-free toxin, and a carrier suitable for internal administration.
2. The vaccine composition of claim 1, further comprising an immunogenic amount of one or more additional antigens.
3. The vaccine composition of claim 2, wherein said additional antigens are selected from the group consisting of a Bordetella bronchiseptica bacterin, an Erysipelothrix rhusiopathiae bacterin, inactivated Mycoplasma hyopneumoniae, and Escherichia coli antigens.
4. The vaccine composition of claim 1, wherein said Pasteurella multocida bacterin is prepared from a toxigenic Type D strain.
5. The vaccine composition of claim 4, wherein said toxigenic Type D strain is Pasteurella multocida Type D strain 8.
6. The vaccine composition of claim 1, further comprising one or more adjuvants.
7. The vaccine composition of claim 6, wherein said adjuvants are selected from the group consisting of dispersed oils, mineral oil and lecithin emulsion, Al.sub.2 OH.sub.3, muramyl dipeptide, saponins, and Quil A.
8. The vaccine composition of claim 6, wherein said adjuvants are dispersed oils and Al.sub.2 OH.sub.3.
9. A method of vaccinating an animal against Pasteurella multocida comprising internally administering to said animal the vaccine composition of claim 1.
10. The method of claim 9 wherein said vaccine composition further comprises an immunogeneic amount of one or more additional antigens, said additional antigens selected from the group consisting of a Bordetella bronchiseptica bacterin, an Erysipelothrix rhusiopathiae bacterin, inactivated Mycoplasma hyopneumoniae, and Escherichia coli antigens.
11. The method of claim 9 wherein said vaccine composition further comprises one or more adjuvants.
12. The method of claim 11 wherein said adjuvants are selected from the group consisting of dispersed oils, mineral oil and lecithin emulsion, Al.sub.2 OH.sub.3, muramyl dipeptide, saponins, and Quil A.
13. The method of claim 11 wherein said adjuvants are dispersed oils and Al.sub.2 OH.sub.3.
14. A method of vaccinating an animal against Pasteurella multocida comprising the sequential steps of internally administering to said animal an immunogenic amount of a Pasteurella multocida bacterin, said bacterin comprising a cell-bound toxoid, and internally administering to said animal an immunogenic amount of an alkaline-toxoided Pasteurella multocida cell-free toxin.
- Bescham Laboratories Atrobac 3 No. pp. 1-7, 1989. Pejsak et al. J. Vet Meth. B. 37: 543-598, 1990. Layton et al Avian Diseases 28:1086-1095, 1984. Animal-Pharm 186 p. 22 Beecham's Lab's New Pig Vaccine Aug. 18, 1989. Kohisch et al The Veterinary Record 124:57-61 1989. Database Search: Animal Pharm, Showing veterinary biological licences issued in May 1989. Daniel et al Proceedings American Association of Swine Practitioners, Mar. 1986, pp. 77-95. J.C. Baars et al., 1986, Proc. Int'l. Pig Vet. Soc., 9th Cong., Challenge and field experiments with an experimental atrophic rhinitis vaccine, containing Pasterella mutocida DNT-toxoid and Bordetella bronchiseptica, p. 247. K. Barfod et al., 1984, Nord. Vet.-Med. 36:337-345, Influence of vaccination of sows with Bordetella-Pasteurella vaccines on the occurrence of atrophic rhinitis among their offspring after experimental infection with Bordetella bronchiseptica and toxigenic Pasteurella multocida. M.F. de Jong et al., 1986, Proc. Int'l. Pig Vet. Soc., 9th Cong., Neutralization-test against AR-toxin of Pasteurella multocida in pig herds after vaccination with Ar-vaccines. M. F. de Jong et al., 1984, Proc. Int'l. Pig Vet. Soc., 8th Cong., Atrophic rhinitis in pigs induced by the intramuscular administering of "the Ar-toxin" containing bacteria-free broth culture filtrate, p. 161. J. Descamps et al., 1986, Proc. Int'l. Pig Vet. Soc., 9th Cong., Vaccination study for protection against the dermonecrotic toxin of Pasteurella multocida type D. N.T. Foged et al., 1989, Vet. Rec., 125:7-11, Protection against progressive atrophic rhinitis by vaccination with Pasteurella multocida toxin purified by monoclonal antibodies. K.L. Heddleston et al., 1966, J. Immun., 96:124-133, Immunizing and toxic properties of particulate antigens from two immunogenic types of Pasteurella multocida of avian origin. J.Y. Kim et al., 1986, Res. Rept., 28:77-93, Studies on immunogenicity of Pasteurella multocida isolated from swine in Korea (Abstract in English). Y.S. Lu et al., 1987, Infect. Immun., 55:2967-2976, A potassium thiocyanate vaccine prepared from Pasteurella multocida 3:A protects rabbits against homologous challenge. M. Matsumoto et al., 1977, Avian Dis., 21:382-393, A bacterin against fowl cholera in turkeys: protective quality of various preparations originated from broth cultures. T.K.S. Mukkur, 1979, J. Gen. Microbiol., 113:37-43, Immunogenicity of a chaotropically extracted protective antigen(s) of Pasteurella multocida type A (bovine origin) against experimental Pasteurellosis in mice. T. Nakai et al., 1984, Infect. Immun., 46:429-434, Purification of dermonecrotic toxin from a sonic extract of Pasteurella multocida S72 serotype D. J. M. Park et al., 1988, Res. Rep. Rural Dev. Adm., 30:28-36, Studies on the combined vaccine of swine bacterial diseases containing Pasteurella-multocida Bordetella-bronchiseptica Erysipelothrix-rhusiopathiae Escherichia-coli (Abstract only). K. B. Pedersen et al., 1981, Nord. Vet. Med., 33:513-522, The aetiological significance of Bordetella bronchiseptica and Pasteurella multocida in atrophic rhinitis of swine. K. B. Pedersen et al., 1982, Nord. Vet. Med., 34:293-302, Effect on the incidence of atrophic rhinitis of vaccination of sows with a vaccine containing Pasteurella multocida toxin. P. A. Rebers et al., 1984, Carb Res., 133:83-94, The effect of formalin-killing of Pasteurella multocida on the antigenicity and extractability of its lipopolysaccharide. J. M. Rutter, 1983, Res. Vet. Science, 34:287-295, Virulence of Pasteurella multocida in atrophic rhinitis of gnotobiotic pigs infected with Bordetella bronchiseptica. D. Schimmel, 1990, Berl. Munch. Tier. Woch., 103:410-411, Further development of Pasteurella multocida vaccines for pigs (Abstract only). R. Singh et al., 1988, Singapore J. Primary Industries, 16:24-33, Efficacy of an inactivated broth-grown Pasteurella multocida bacterin in ducklings (Abstracts only).
Type: Grant
Filed: Jul 11, 1994
Date of Patent: Dec 9, 1997
Assignee: Pfizer Inc. (New York, NY)
Inventors: Joseph C. Frantz (Lincoln, NE), David S. Roberts (Lincoln, NE), Leroy A. Swearingin (Lincoln, NE), Richard J. Kemmy (Gretna, NE)
Primary Examiner: Hazel F. Sidberry
Attorneys: Peter C. Richardson, Paul H. Ginsburg, Alan L. Koller
Application Number: 8/244,052
International Classification: A61K 39102; A61K 3910; A61K 39116; A61K 3902;
